US Blacks Underrepresented in Cardiovascular Drug Trials
Black residents accounted for 2.9 percent of participants in clinical trials for cardiovascular drugs approved by the FDA from 2006 to 2020
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.